Identification of the Β-Catenin/JNK/Prothymosin-Alpha Axis as a Novel Target of Sorafenib in Hepatocellular Carcinoma Cells

Oncotarget - United States
doi 10.18632/oncotarget.5738
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Cytotoxicity of Sorafenib in Human Hepatocellular Carcinoma Cells

Al-Azhar Journal of Pharmaceutical Sciences
2015English

A miR-7/GAS6/TYRO3 Axis Regulates the Growth and Invasiveness of Sorafenib-Resistant Cells in Human Hepatocellular Carcinoma

Hepatology
MedicineHepatology
2017English

Sorafenib in Hepatocellular Carcinoma

Clinical Medicine. Therapeutics
2009English

Tankyrase Inhibitors Attenuate WNT/β-catenin Signaling and Inhibit Growth of Hepatocellular Carcinoma Cells

Oncotarget
Oncology
2015English

Identification of CELSR2 as a Novel Prognostic Biomarker for Hepatocellular Carcinoma

BMC Cancer
Cancer ResearchOncologyGenetics
2020English

Quantitative Phosphoproteomic Analysis Identifies the Potential Therapeutic Target EphA2 for Overcoming Sorafenib Resistance in Hepatocellular Carcinoma Cells

Experimental and Molecular Medicine
BiochemistryMedicineClinical BiochemistryMolecular BiologyMolecular Medicine
2020English

Activation of JNK and High Expression Level of CD133 Predict a Poor Response to Sorafenib in Hepatocellular Carcinoma

British Journal of Cancer
Cancer ResearchOncology
2012English

DLK1 as a Potential Target Against Cancer Stem/Progenitor Cells of Hepatocellular Carcinoma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2012English

Identification of the Typical miRNAs and Target Genes in Hepatocellular Carcinoma

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy